Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review (Q38051600)

27 August 2017

0 references

Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review (English)

1 reference

27 August 2017

main subject

hepatocellular carcinoma

1 reference

Xin Zhang

1

1 reference

27 August 2017

Xin-Rong Yang

2

1 reference

27 August 2017

Xiao-Wu Huang

3

1 reference

27 August 2017

Wei-Min Wang

4

1 reference

27 August 2017

Ruo-Yu Shi

5

1 reference

27 August 2017

Yang Xu

6

1 reference

27 August 2017

Zheng Wang

7

1 reference

27 August 2017

Shuang-Jian Qiu

8

1 reference

27 August 2017

Jia Fan

9

1 reference

27 August 2017

Jian Zhou

10

1 reference

27 August 2017

publication date

1 October 2012

1 reference

Hepatobiliary & Pancreatic Diseases International

27 August 2017

published in

1 reference

27 August 2017

volume

11

1 reference

27 August 2017

issue

5

1 reference

27 August 2017

page(s)

458-466

1 reference

27 August 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2812%2960209-4

7 January 2021

The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2812%2960209-4

7 January 2021

Treatment and prognosis of hepatocellular carcinoma: a population based study in France.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2812%2960209-4

7 January 2021

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2812%2960209-4

7 January 2021

Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2812%2960209-4

7 January 2021

Molecular targeted therapies in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2812%2960209-4

7 January 2021

Sorafenib for the treatment of unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2812%2960209-4

7 January 2021

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2812%2960209-4

7 January 2021

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2812%2960209-4

7 January 2021

Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2812%2960209-4

7 January 2021

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2812%2960209-4

7 January 2021

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2812%2960209-4

7 January 2021

Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2812%2960209-4

7 January 2021

Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2812%2960209-4

7 January 2021

Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2812%2960209-4

7 January 2021

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2812%2960209-4

7 January 2021

Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2812%2960209-4

7 January 2021

Practical methods for incorporating summary time-to-event data into meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2812%2960209-4

7 January 2021

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2812%2960209-4

7 January 2021

Operating characteristics of a rank correlation test for publication bias

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2812%2960209-4

7 January 2021

Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2812%2960209-4

7 January 2021

Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2812%2960209-4

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2812%2960209-4

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2812%2960209-4

7 January 2021

Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2812%2960209-4

7 January 2021

Serum Markers of Hepatocellular Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2812%2960209-4

7 January 2021

Mechanisms of adverse effects of anti-VEGF therapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2812%2960209-4

7 January 2021

Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2812%2960209-4

7 January 2021

Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2812%2960209-4

7 January 2021

Managing side effects of angiogenesis inhibitors in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2812%2960209-4

7 January 2021

Sorafenib: a promising new targeted therapy for renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2812%2960209-4

7 January 2021

10.1016/S1499-3872(12)60209-4

Identifiers

DOI

0 references

1 reference